Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia

Journal of Clinical Oncology

Volumn 19, Issue 5, 2001, Pages 1414-1420

  O'Brien, S M ^a   Kantarjian, H M ^a   Cortes, J ^a   Beran, M ^a   Koller, C A ^a   Giles, F J ^a   Lerner, S ^a   Keating, M ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; FLUDARABINE; ONDANSETRON;

ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; CANCER GRADING; CANCER REGRESSION; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; FLOW CYTOMETRY; HUMAN; MAJOR CLINICAL STUDY; NEUTROPENIA; PNEUMONIA; PRIORITY JOURNAL; SEPSIS;

EID: 0035282055     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.5.1414     Document Type: Article

References (19)

1. Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy
2. A randomized comparison of fludarabine and chlorambucil for patients with previously untreated chronic lymphocytic leukemia: A CALBG, SWOG, CTG/NCI-C and ECOG Intergroup study
3. Purine nucleoside analogs: Emerging roles in indolent lymphoproliferative disorders
4. Multicentre prospective randomized trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukemia
5. Clinical experience with fludarabine and its immunosuppressive effects in pretreated chronic lymphocytic leukemias and low-grade lymphomas
6. Treatment of advanced chronic lymphocytic leukemia by fludarabine: Results of a clinical study
7. Fludarabine: A new agent with major activity against chronic lymphocytic leukemia
8. Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment
9. Fludarabine and cyclophosphamide: Synergistic cytotoxicity associated with inhibition of interstrand cross-link removal
10. In vitro evaluation of fludarabine in combination with cyclophosphamide and/or mitoxantrone in B-cell chronic lymphocytic leukemia
11. National Cancer Institute - Sponsored Working Group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment
12. Evaluation of survival data and two new rank order statistics arising to consideration
13. Non-parametric estimation from incomplete observations
14. Fludarabine, as well as 2-chlorodeoxyadenosine, can induce eosinophilia during treatment of lymphoid malignancies
15. 2-Chlorodeoxyadenosine (cladribine)-related eosinophilia in patients with lymphoproliferative diseases
16. Concomitant administration of chlorambucil limits dose intensity of fludarabine in previously treated patients with chronic lymphocytic leukemia
17. A phase I trial of combination fludarabine monophosphate and chlorambucil in chronic lymphocytic leukemia: A Southwest Oncology Group study
18. Fludarabine and cyclophosphamide with filgrastim support in patients with previously untreated indolent lymphoid malignancies
19. Fludarabine plus cyclophosphamide (FC) and dose-intensified chlorambucil (DIC) for the treatment of chronic lymphocytic leukemia (CLL): Results of two phase II studies (CLL2-protocol) of the German CLL Study Group (GCLLSG)